TY - JOUR
T1 - MYC protein expression is an important prognostic factor in acute myeloid leukemia
AU - Ohanian, Maro
AU - Rozovski, Uri
AU - Kanagal-Shamanna, Rashmi
AU - Abruzzo, Lynne V.
AU - Loghavi, Sanam
AU - Kadia, Tapan
AU - Futreal, Andrew
AU - Bhalla, Kapil
AU - Zuo, Zhuang
AU - Huh, Yang O.
AU - Post, Sean M.
AU - Ruvolo, Peter
AU - Garcia-Manero, Guillermo
AU - Andreeff, Michael
AU - Kornblau, Steven
AU - Borthakur, Gautam
AU - Hu, Peter
AU - Medeiros, L. Jeffrey
AU - Takahashi, Koichi
AU - Hornbaker, Marisa J.
AU - Zhang, Jianhua
AU - Nogueras-González, Graciela M.
AU - Huang, Xuelin
AU - Verstovsek, Srdan
AU - Estrov, Zeev
AU - Pierce, Sherry
AU - Ravandi, Farhad
AU - Kantarjian, Hagop M.
AU - Bueso-Ramos, Carlos E.
AU - Cortes, Jorge E.
N1 - Funding Information:
This work was supported in part by Leukemia SPORE Grant P50CA100632 from the National Institutes of Health. SMP was supported by a National Cancer Institute/National Institutes of Health Award (R01CA207204).
Publisher Copyright:
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/1/2
Y1 - 2019/1/2
N2 - As new drugs targeting MYC show clinical activity in acute myeloid leukemia (AML), understanding MYC expression in AML is of critical importance. We assessed MYC protein expression by immunohistochemistry in bone marrow of patients with untreated AML (n = 265). Overall, 90% of patients demonstrated MYC overexpression and MYC immunopositivity ≤6% was associated with superior complete remission (CR) duration of 23 months versus 12 months for MYC immunopositivity >6% (p =.028). Among 241 patients at higher risk for relapse, including those ≥55 years of age and patients with intermediate- and high-risk AML, MYC immunopositivity ≤6% conferred significantly superior median overall survival (OS) (24 versus 13 months; p =.042), event-free survival (EFS) (14 versus 6 months; p =.048), and relapse-free survival (RFS) (25 versus 12 months; p =.024). The prognostic impact of MYC-immunopositivity was retained on multivariate analysis of OS, EFS, and RFS. We conclude that MYC immunopositivity is an important prognostic factor in patients with untreated AML, particularly those at higher risk for relapse.
AB - As new drugs targeting MYC show clinical activity in acute myeloid leukemia (AML), understanding MYC expression in AML is of critical importance. We assessed MYC protein expression by immunohistochemistry in bone marrow of patients with untreated AML (n = 265). Overall, 90% of patients demonstrated MYC overexpression and MYC immunopositivity ≤6% was associated with superior complete remission (CR) duration of 23 months versus 12 months for MYC immunopositivity >6% (p =.028). Among 241 patients at higher risk for relapse, including those ≥55 years of age and patients with intermediate- and high-risk AML, MYC immunopositivity ≤6% conferred significantly superior median overall survival (OS) (24 versus 13 months; p =.042), event-free survival (EFS) (14 versus 6 months; p =.048), and relapse-free survival (RFS) (25 versus 12 months; p =.024). The prognostic impact of MYC-immunopositivity was retained on multivariate analysis of OS, EFS, and RFS. We conclude that MYC immunopositivity is an important prognostic factor in patients with untreated AML, particularly those at higher risk for relapse.
KW - Acute myeloid leukemia (AML)
KW - MYC
KW - immunohistochemistry (IHC)
UR - http://www.scopus.com/inward/record.url?scp=85046688405&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046688405&partnerID=8YFLogxK
U2 - 10.1080/10428194.2018.1464158
DO - 10.1080/10428194.2018.1464158
M3 - Article
C2 - 29741984
AN - SCOPUS:85046688405
SN - 1042-8194
VL - 60
SP - 37
EP - 48
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 1
ER -